|
|
|
|
| LEADER |
05740nma a2201453 u 4500 |
| 001 |
EB002196922 |
| 003 |
EBX01000000000000001334387 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
240202 ||| eng |
| 020 |
|
|
|a 9783036597492
|
| 020 |
|
|
|a 9783036597485
|
| 020 |
|
|
|a books978-3-0365-9749-2
|
| 100 |
1 |
|
|a Stepien, Karolina M.
|
| 245 |
0 |
0 |
|a Management of Acute and Chronic Complications of Lysosomal Storage Diseases in Children and Adults: Current Practice and Future Opportunities
|h Elektronische Ressource
|
| 260 |
|
|
|a Basel
|b MDPI - Multidisciplinary Digital Publishing Institute
|c 2023
|
| 300 |
|
|
|a 1 electronic resource (266 p.)
|
| 653 |
|
|
|a corneal clouding
|
| 653 |
|
|
|a intratracheal
|
| 653 |
|
|
|a speech
|
| 653 |
|
|
|a Mucopolysaccharidosis
|
| 653 |
|
|
|a cognition
|
| 653 |
|
|
|a acoustic
|
| 653 |
|
|
|a perfusion
|
| 653 |
|
|
|a Niemann-Pick type B
|
| 653 |
|
|
|a adult metabolic medicine
|
| 653 |
|
|
|a MPS
|
| 653 |
|
|
|a airway
|
| 653 |
|
|
|a voice
|
| 653 |
|
|
|a management
|
| 653 |
|
|
|a inherited metabolic disorders
|
| 653 |
|
|
|a mucolipidosis
|
| 653 |
|
|
|a respiratory
|
| 653 |
|
|
|a transition service
|
| 653 |
|
|
|a morbidity
|
| 653 |
|
|
|a acid sphingomyelinase
|
| 653 |
|
|
|a anaesthesia
|
| 653 |
|
|
|a translational research
|
| 653 |
|
|
|a gastrointestinal
|
| 653 |
|
|
|a mortality
|
| 653 |
|
|
|a dysphonia
|
| 653 |
|
|
|a perinatal-lethal Gaucher disease
|
| 653 |
|
|
|a neuropathic pain
|
| 653 |
|
|
|a late-onset Pompe disease
|
| 653 |
|
|
|a neurofilament light
|
| 653 |
|
|
|a atherosclerosis
|
| 653 |
|
|
|a obstruction
|
| 653 |
|
|
|a mucopolysaccharidosis
|
| 653 |
|
|
|a angina
|
| 653 |
|
|
|a enzyme replacement therapy
|
| 653 |
|
|
|a perioperative complications
|
| 653 |
|
|
|a GBA gene
|
| 653 |
|
|
|a health care providers
|
| 653 |
|
|
|a surgery
|
| 653 |
|
|
|a Fabry disease
|
| 653 |
|
|
|a disease manifestations
|
| 653 |
|
|
|a challenges
|
| 653 |
|
|
|a GAA
|
| 653 |
|
|
|a I-cell disease
|
| 653 |
|
|
|a Sanfilippo syndrome
|
| 653 |
|
|
|a collaboration
|
| 653 |
|
|
|a fabry disease
|
| 653 |
|
|
|a MLII
|
| 653 |
|
|
|a pompe disease
|
| 653 |
|
|
|a Medicine and Nursing / bicssc
|
| 653 |
|
|
|a attention
|
| 653 |
|
|
|a ichthyosis
|
| 653 |
|
|
|a glycogen storage disorder
|
| 653 |
|
|
|a depression
|
| 653 |
|
|
|a Pompe disease
|
| 653 |
|
|
|a symptoms
|
| 653 |
|
|
|a deep anterior lamellar keratoplasty
|
| 653 |
|
|
|a PLGD
|
| 653 |
|
|
|a Attention Deficit/Hyperactivity
|
| 653 |
|
|
|a lysosomal storage disease (LSD)
|
| 653 |
|
|
|a smooth muscles
|
| 653 |
|
|
|a intubation
|
| 653 |
|
|
|a NIHF
|
| 653 |
|
|
|a inherited metabolic diseases
|
| 653 |
|
|
|a neurological disease
|
| 653 |
|
|
|a PROMIS-GI symptom scales
|
| 653 |
|
|
|a dried-blood spots
|
| 653 |
|
|
|a COVID-19
|
| 653 |
|
|
|a ML II
|
| 653 |
|
|
|a Niemann-Pick type A
|
| 653 |
|
|
|a biomarkers
|
| 653 |
|
|
|a trehalose
|
| 653 |
|
|
|a healthcare systems
|
| 653 |
|
|
|a mucolipidosis type II
|
| 653 |
|
|
|a patient-reported outcomes measures
|
| 653 |
|
|
|a GAAKO mice
|
| 653 |
|
|
|a hyperparathyroidism
|
| 653 |
|
|
|a hyoid bone
|
| 653 |
|
|
|a chin
|
| 653 |
|
|
|a Neurology and clinical neurophysiology / bicssc
|
| 653 |
|
|
|a spine disease
|
| 653 |
|
|
|a sphingolipid deposition
|
| 653 |
|
|
|a gene panel sequencing
|
| 653 |
|
|
|a glycogen storage disease type II
|
| 653 |
|
|
|a airway management
|
| 653 |
|
|
|a alpha-glucosidase
|
| 653 |
|
|
|a ML
|
| 653 |
|
|
|a mucopolysaccharidoses
|
| 653 |
|
|
|a Niemann-Pick C
|
| 653 |
|
|
|a Gaucher disease
|
| 653 |
|
|
|a ischaemia
|
| 653 |
|
|
|a GRBAS
|
| 653 |
|
|
|a radiology
|
| 653 |
|
|
|a Fabry
|
| 653 |
|
|
|a penetrating keratoplasty
|
| 653 |
|
|
|a auditory-perceptual
|
| 653 |
|
|
|a rare autoinflammatory diseases
|
| 700 |
1 |
|
|a Hendriksz, Christian J.
|
| 700 |
1 |
|
|a Pastores, Gregory M
|
| 700 |
1 |
|
|a Stepien, Karolina M.
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b DOAB
|a Directory of Open Access Books
|
| 500 |
|
|
|a Creative Commons (cc), https://creativecommons.org/licenses/by/4.0/
|
| 028 |
5 |
0 |
|a 10.3390/books978-3-0365-9749-2
|
| 856 |
4 |
2 |
|u https://directory.doabooks.org/handle/20.500.12854/132422
|z DOAB: description of the publication
|
| 856 |
4 |
0 |
|u https://www.mdpi.com/books/pdfview/book/8458
|7 0
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 612
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a This reprint, entitled "Management of Acute and Chronic Complications of Lysosomal Storage Diseases in Children and Adults: Current Practice and Future Opportunities", covers broad aspects of this group of rare diseases. The first theme includes articles on the management of pain, corneal clouding, gastrointestinal and airway diseases in Mucopolysaccharidoses and Mucolipidoses, and the evaluation of dysphonia in Pompe disease. Additionally, attention deficit and ADHD and the management of atherosclerosis in Fabry disease are considered here. The second theme includes diagnostic conundrums in lysosomal storage diseases, e.g., the prenatal diagnosis of Gaucher disease during pregnancy, the diagnosis of secondary hyperparathyroidism in Mucolipidoses, and the application of the new biomarker "plasma neurofilament light" in Niemann Pick C disease, as well as the correlation of enzyme activity with molecular diagnosis in Pompe disease. The articles in the third theme describe the impact of therapies on clinical outcomes. For example, a systematic review of the impact of enzyme replacement therapy on late-onset Pompe disease and trehalose use on Niemann Pick A and B is included. The remaining articles describe the NHS processes for overcoming challenges resulting from the COVID-19 pandemic and the differences in the transition from paediatric to adult services between different countries.
|